We are testing a new treatment, ABO-101, to see if it is safe and well-tolerated in people with Primary Hyperoxaluria Type 1. The study will also explore how the body reacts to the treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
Primary Hyperoxaluria is a rare genetic disorder that causes the body to produce too much oxalate, which can lead to kidney stones and kidney damage. It is primarily caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.